Is Dexcom Inc (NASDAQ:DXCM)’s Fuel Running High? Reports Show Less Sellers

May 25, 2018 - By Kurt Siggers

DexCom, Inc. (NASDAQ:DXCM) Logo

Investors sentiment decreased to 0.73 in 2017 Q4. Its down 0.24, from 0.97 in 2017Q3. It dived, as 44 investors sold DexCom, Inc. shares while 97 reduced holdings. 48 funds opened positions while 55 raised stakes. 99.11 million shares or 0.83% more from 98.30 million shares in 2017Q3 were reported.
Bamco reported 301,000 shares. Goldman Sachs Grp invested 0.02% in DexCom, Inc. (NASDAQ:DXCM). Macquarie Grp Limited has 0.02% invested in DexCom, Inc. (NASDAQ:DXCM) for 188,177 shares. Earnest Ptnrs Ltd Liability reported 33 shares stake. Wells Fargo And Co Mn has 128,019 shares for 0% of their portfolio. Bluestein R H And Communications invested 0.03% in DexCom, Inc. (NASDAQ:DXCM). Regions Financial Corporation invested 0.01% in DexCom, Inc. (NASDAQ:DXCM). Invesco owns 1.28M shares for 0.03% of their portfolio. Price T Rowe Assocs Md has 9.99 million shares. Axa stated it has 0.43% of its portfolio in DexCom, Inc. (NASDAQ:DXCM). Waddell And Reed Financial stated it has 260,000 shares. Moreover, Grandeur Peak Advsr Lc has 0.05% invested in DexCom, Inc. (NASDAQ:DXCM) for 6,400 shares. Parallax Volatility Advisers Ltd Partnership has 6,551 shares. Weatherly Asset Management Lp reported 0.11% in DexCom, Inc. (NASDAQ:DXCM). 395 were accumulated by C M Bidwell Assoc Ltd.

Since December 11, 2017, it had 0 insider purchases, and 16 sales for $13.22 million activity. Leach Jacob Steven also sold $1.12 million worth of DexCom, Inc. (NASDAQ:DXCM) shares. DOUBLEDAY RICHARD also sold $176,643 worth of DexCom, Inc. (NASDAQ:DXCM) on Friday, March 23. 3,245 DexCom, Inc. (NASDAQ:DXCM) shares with value of $198,691 were sold by Balo Andrew K. GREGG TERRANCE H sold $568,588 worth of stock or 10,000 shares. Shares for $2.68M were sold by SKYLER JAY S.

The stock of Dexcom Inc (NASDAQ:DXCM) registered a decrease of 1.61% in short interest. DXCM’s total short interest was 12.40M shares in May as published by FINRA. Its down 1.61% from 12.60 million shares, reported previously. With 843,400 shares average volume, it will take short sellers 15 days to cover their DXCM’s short positions. The short interest to Dexcom Inc’s float is 14.49%.

The stock increased 0.58% or $0.51 during the last trading session, reaching $87.99. About 244,219 shares traded. DexCom, Inc. (NASDAQ:DXCM) has declined 16.08% since May 25, 2017 and is downtrending. It has underperformed by 27.63% the S&P500.

DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. The company has market cap of $7.75 billion. The firm offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. It currently has negative earnings. The Company’s products include DexCom G4 PLATINUM system for continuous use by adults with diabetes; DexCom G4 PLATINUM with Share, a remote monitoring system; and DexCom G5 Mobile, a CGM system that directly communicates to a patientÂ’s mobile and its data can be integrated with DexCom CLARITY, which is a next generation cloud reporting software for personalized, easy-to-understand analysis of trends to improve diabetes management.

DexCom, Inc. (NASDAQ:DXCM) Ratings Coverage

Among 12 analysts covering Dexcom (NASDAQ:DXCM), 8 have Buy rating, 2 Sell and 2 Hold. Therefore 67% are positive. Dexcom had 20 analyst reports since December 12, 2017 according to SRatingsIntel. The stock of DexCom, Inc. (NASDAQ:DXCM) earned “Buy” rating by Jefferies on Thursday, December 21. Cowen & Co maintained DexCom, Inc. (NASDAQ:DXCM) rating on Wednesday, December 20. Cowen & Co has “Buy” rating and $70.0 target. As per Thursday, January 4, the company rating was downgraded by Northland Capital. Robert W. Baird upgraded the shares of DXCM in report on Friday, March 23 to “Outperform” rating. The company was maintained on Wednesday, April 11 by Cowen & Co. The stock of DexCom, Inc. (NASDAQ:DXCM) has “Outperformer” rating given on Thursday, May 3 by BMO Capital Markets. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, March 28. Morgan Stanley maintained DexCom, Inc. (NASDAQ:DXCM) rating on Friday, May 4. Morgan Stanley has “Equal-Weight” rating and $70 target. The firm has “Buy” rating given on Wednesday, January 17 by BMO Capital Markets. The company was maintained on Monday, April 9 by Stephens.

More notable recent DexCom, Inc. (NASDAQ:DXCM) news were published by: Seekingalpha.com which released: “DexCom (DXCM) Q1 2018 Results – Earnings Call Transcript” on May 03, 2018, also Profitconfidential.com with their article: “DXCM Stock Is on the Verge of Breaking Out Toward Higher Prices” published on May 09, 2018, Investorplace.com published: “The 10 Fastest-Growing Stocks to Invest In Right Now” on May 22, 2018. More interesting news about DexCom, Inc. (NASDAQ:DXCM) were released by: Nasdaq.com and their article: “Here’s Why Tandem Diabetes Care, Inc. Is Rising Today” published on May 14, 2018 as well as Benzinga.com‘s news article titled: “Piper Jaffray: Tandem Diabetes Is Entering A ‘Goldilocks Period'” with publication date: May 14, 2018.

DexCom, Inc. (NASDAQ:DXCM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.